Evidence map›Paper›PMID 36935504›Full record

ArticleEuropean journal of medical research2023

Multi-omics to predict acute radiation esophagitis in patients with lung cancer treated with intensity-modulated radiation therapy.

Xiaoli Zheng, Wei Guo, Yunhan Wang, Jiang Zhang, Yuanpeng Zhang, Chen Cheng, Xinzhi Teng, Saikit Lam, Ta Zhou, Zongrui Ma and 5 more

Open access · goldFull text read
In one paragraph

Article in European journal of medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Multiomic random forest toxicity modeling of radiation esophagitis.Physics and imaging in radiation oncology · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Xiaoli ZhengDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Wei GuoDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Yunhan WangDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Jiang ZhangDepartment of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong SAR, China.
Yuanpeng ZhangDepartment of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong SAR, China.
Chen ChengDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Xinzhi TengDepartment of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong SAR, China.
Saikit LamDepartment of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong SAR, China.
Ta ZhouDepartment of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong SAR, China.
Zongrui MaDepartment of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong SAR, China.
Ruining LiuDepartment of Interventional Therapy, Henan Provincial People's Hospital, Zhengzhou, China.
Hui WuDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Hong GeDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. zlyygehong0199@zzu.edu.cn.
Jing CaiDepartment of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong SAR, China. jing.cai@polyu.edu.hk.
Bing LiDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. zlyylibing4127@zzu.edu.cn.
Hong Kong Polytechnic University · HKZhengzhou University · CNHenan Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe study aimed to predict acute radiation esophagitis (ARE) with grade  ≥ 2 for patients with locally advanced lung cancer (LALC) treated with intensity-modulated radiation therapy (IMRT) using multi-omics features, including radiomics and dosiomics.

methods161 patients with stage IIIA-IIIB LALC who received chemoradiotherapy (CRT) or radiotherapy by IMRT with a prescribed dose from 45 to 70 Gy from 2015 to 2019 were enrolled retrospectively. All the toxicity gradings were given following the Common Terminology Criteria for Adverse Events V4.0. Multi-omics features, including radiomics, dosiomics (including dose-volume histogram dosimetric parameters), were extracted based on the planning CT image and three-dimensional dose distribution. All data were randomly divided into training cohorts (N = 107) and testing cohorts (N = 54). In the training cohorts, features with reliably high outcome relevance and low redundancy were selected under random patient subsampling. Four classification models (using clinical factors (CF) only, using radiomics features (RFs) only, dosiomics features (DFs) only, and the hybrid features (HFs) containing clinical factors, radiomics and dosiomics) were constructed employing the Ridge classifier using two-thirds of randomly selected patients as the training cohort. The remaining patient was treated as the testing cohort. A series of models were built with 30 times training-testing splits. Their performances were assessed using the area under the ROC curve (AUC) and accuracy.

resultsAmong all patients, 51 developed ARE grade  ≥ 2, with an incidence of 31.7%. Next, 8990 radiomics and 213 dosiomics features were extracted, and 3, 6, 12, and 13 features remained after feature selection in the CF, DF, RF and DF models, respectively. The RF and HF models achieved similar classification performance, with the training and testing AUCs of 0.796 ± 0.023 (95% confidence interval (CI [0.79, 0.80])/0.744 ± 0.044 (95% CI [0.73, 0.76]) and 0.801 ± 0.022 (95% CI [0.79, 0.81]) (p = 0.74), respectively. The model performances using CF and DF features were poorer, with training and testing AUCs of 0.573 ± 0.026 (95% CI [0.56, 0.58])/ 0.509 ± 0.072 (95% CI [0.48, 0.53]) and 0.679 ± 0.027 (95% CI [0.67, 0.69])/0.604 ± 0.041 (95% CI [0.53, 0.63]) compared with the above two models (p < 0.001), respectively.

conclusionsIn LALC patients treated with CRT IMRT, the ARE grade  ≥ 2 can be predicted using the pretreatment radiotherapy image features. To predict ARE, the multi-omics features had similar predictability with radiomics features; however, the dosiomics features and clinical factors had a limited classification performance.

Indexed as

EsophagitisLung NeoplasmsRadiotherapy, Intensity-ModulatedHumansMultiomicsRadiotherapy DosageRetrospective StudiesAcute radiation esophagitisDosiomicsLung cancerMachine learningRadiomicsRadiotherapy

Identifiers

PMID36935504
PMCPMC10024847
OpenAlexW4327892910

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read85
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.